Thiazoles, including 2,7-dimethylthiazolo[4,5-d]pyradazine-4-(5H)-thione (4b) and the corresponding 5-phenylthiazolo[4,5-d]pyradazine-4-methylthiol (5a), were synthesized as part of an ongoing investigation into corticotrophin-releasing hormone (CRH) type 1 receptor activity. Subsequent screening indicated the successful discovery of receptor agonists. Assay results indicated a 52 and 3% increase in β-endorphin release after the administration of 100 M (4b) and (5a), respectively. It is believed that this represents the first evidence of this class of compounds displaying CRH type 1 receptor agonist activity.